Tara Anderson

724 total citations
10 papers, 406 citations indexed

About

Tara Anderson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Tara Anderson has authored 10 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Tara Anderson's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Tara Anderson is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Tara Anderson collaborates with scholars based in United States, Poland and Italy. Tara Anderson's co-authors include Daniel Lebovic, Kent A. Griffith, Andrzej Jakubowiak, Ravi Vij, Sundar Jagannath, Keith Stockerl‐Goldstein, Dominik Dytfeld, Kristen Detweiler‐Short, Mark Kaminski and Daniel R. Couriel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Tara Anderson

10 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tara Anderson United States 6 361 330 173 38 32 10 406
Cecilia Rus Italy 5 361 1.0× 248 0.8× 203 1.2× 20 0.5× 34 1.1× 12 378
Miguel Teodoro Hernández‐Garcia Spain 6 328 0.9× 264 0.8× 168 1.0× 14 0.4× 39 1.2× 10 373
Edvan de Queiroz Crusoé Brazil 8 229 0.6× 233 0.7× 156 0.9× 16 0.4× 33 1.0× 41 353
Clotilde Cangialosi Italy 8 433 1.2× 365 1.1× 259 1.5× 17 0.4× 30 0.9× 16 460
Antonio Palumbo Netherlands 3 430 1.2× 355 1.1× 252 1.5× 11 0.3× 39 1.2× 5 451
Sara Bringhen Italy 3 376 1.0× 310 0.9× 224 1.3× 11 0.3× 35 1.1× 4 397
Evžen Gregora Czechia 11 253 0.7× 218 0.7× 130 0.8× 14 0.4× 43 1.3× 29 301
Ammar Al-Zoubi United States 5 377 1.0× 370 1.1× 200 1.2× 25 0.7× 71 2.2× 11 455
S Triolo Italy 7 347 1.0× 223 0.7× 198 1.1× 25 0.7× 36 1.1× 13 367
A. Keith Stewart United States 5 221 0.6× 184 0.6× 118 0.7× 11 0.3× 37 1.2× 13 257

Countries citing papers authored by Tara Anderson

Since Specialization
Citations

This map shows the geographic impact of Tara Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Anderson more than expected).

Fields of papers citing papers by Tara Anderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Anderson. The network helps show where Tara Anderson may publish in the future.

Co-authorship network of co-authors of Tara Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Tara Anderson. A scholar is included among the top collaborators of Tara Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Anderson. Tara Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Li, Fangyong, Terri L. Parker, Noffar Bar, et al.. (2024). Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7559–7559. 1 indexed citations
2.
Bailur, Jithendra Kini, Sameet Mehta, Lin Zhang, et al.. (2017). Early Enrichment and Subsequent Dysfunction of Marrow ILC Subsets in Monoclonal Gammopathy: Target for IMiD Therapy. Blood. 130. 4370. 2 indexed citations
3.
Bailur, Jithendra Kini, Sameet Mehta, Lin Zhang, et al.. (2017). Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances. 1(25). 2343–2347. 34 indexed citations
4.
5.
Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2013). Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.. Journal of Clinical Oncology. 31(15_suppl). 8543–8543. 13 indexed citations
6.
Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 120(9). 1801–1809. 311 indexed citations
7.
Lebovic, Daniel, Mark Kaminski, Tara Anderson, et al.. (2012). A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM). Blood. 120(21). 1854–1854. 7 indexed citations
8.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations
9.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2010). Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. Blood. 116(21). 862–862. 12 indexed citations
10.
Cameron, David, J Craig, Hani Gabra, et al.. (1996). High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. British Journal of Cancer. 74(12). 2013–2017. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cecilia Rus Breakdown of academic impact, for papers by Miguel Teodoro Hernández‐Garcia Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Clotilde Cangialosi Breakdown of academic impact, for papers by Antonio Palumbo Breakdown of academic impact, for papers by Sara Bringhen Breakdown of academic impact, for papers by Evžen Gregora Breakdown of academic impact, for papers by Ammar Al-Zoubi Breakdown of academic impact, for papers by S Triolo Breakdown of academic impact, for papers by A. Keith Stewart
Rankless by CCL
2026